ArticleJournal of translational medicine2025
GM-CSF potentiates macrophages to retain an inflammatory feature from their circulating monocyte precursors in rheumatoid arthritis.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- The Multifaceted Roles of Macrophages in Rheumatoid Arthritis: From Cytokine Networks to the Discovery of Novel Subsets.International journal of molecular sciences · 2026Review
- SHIP blocks (MDP + LPS)-induced synergy in macrophages independent of catalytic activity.Journal of leukocyte biology · 2026Article
- The EGR1/ZFP36 axis governs glycosphingolipid metabolic reprogramming in monocyte-derived macrophages in guillain-barré syndrome.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- Traffic and functional polarization of macrophages in the areas of programmed interdigital cell death in the embryonic chick.Apoptosis : an international journal on programmed cell death · 2026Article
- Roles of immune cell metabolism in rheumatoid arthritis.Frontiers in immunology · 2026Review
- The dual role of metabolic reprogramming in macrophage polarization in rheumatoid arthritis and coronary heart disease and the intervention strategy of traditional Chinese medicine.Frontiers in cardiovascular medicine · 2026Review
- Targeting GM-CSF in Rheumatoid Arthritis: Advances in Cytokine-Directed Immunotherapy and Clinical Implications.Life (Basel, Switzerland) · 2025Review
- Pathogenic Role of Cytokines in Rheumatoid Arthritis.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectivesPeripheral monocytes represent an important source of macrophages in the synovium of rheumatoid arthritis (RA). However, it remains unclear whether the proinflammatory traits in RA monocytes can be maintained during their differentiation into macrophages without exogenous polarization stimuli.
methodsPeripheral blood CD14
resultsTranscriptomic and functional analyses revealed that GM-CSF-differentiated macrophages (GM-DMs) from RA monocytes preserved a proinflammatory M1-like phenotype, whereas M-CSF-differentiated macrophages (M-DMs) lost this phenotype. Synovial GM-CSF expression levels were significantly elevated in RA patients compared to HCs and were positively correlated with disease activity (DAS28-CRP). In contrast, M-CSF expression levels were reduced and inversely correlated with DAS28-CRP. RA GM-DMs exhibited hyperactivation of the STAT5 signaling and a hypermetabolic profile, characterized by enhanced oxidative phosphorylation (OXPHOS) and impaired glycolysis. Strikingly, CCL22 was identified as the most upregulated chemokine in RA GM-DMs. Elevated synovial CCL22 expression strongly correlated with M1 macrophage infiltration and disease activity. Functionally, CCL22 promoted CD4
conclusionGM-CSF supports the maintenance of the proinflammatory nature of RA monocyte-derived macrophages, driving CCL22-mediated T cell responses. This study highlights the GM-CSF/CCL22 axis as a pathogenic mechanism in RA and suggests CCL22 as a novel potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.